Literature DB >> 26512439

Vaginal Mesh in Pelvic Reconstructive Surgery: Controversies, Current Use, and Complications.

Cecile A Unger1, Matthew D Barber.   

Abstract

In 2001, the Food and Drug Administration approved the first surgical mesh product specifically designed for the surgical repair of pelvic organ prolapse and between 2004 and 2008, the use of vaginal mesh in gynecologic surgery was at its peak. Unfortunately, the rise in transvaginal mesh use was accompanied by a surge of adverse events and mesh-related complications. As a result, the Food and Drug Administration put forth several efforts to regulate the manufacturing of vaginal mesh products. These notifications have been supported by several gynecologic societies, and recommendations now exist not only on the placement of mesh and patient selection, but also on the evaluation and management of mesh-related complications. In addition, data on outcomes following management of these complications are now emerging.

Entities:  

Mesh:

Year:  2015        PMID: 26512439     DOI: 10.1097/GRF.0000000000000148

Source DB:  PubMed          Journal:  Clin Obstet Gynecol        ISSN: 0009-9201            Impact factor:   2.190


  3 in total

1.  Feasibility and benefits of the ewe as a model for vaginal surgery training.

Authors:  Yohan Kerbage; Géraldine Giraudet; Chrystèle Rubod; Charles Garabedian; Géraldine Rivaux; Michel Cosson
Journal:  Int Urogynecol J       Date:  2017-03-20       Impact factor: 2.894

2.  Cell derived extracellular matrix fibers synthesized using sacrificial hollow fiber membranes.

Authors:  Kevin Roberts; Jacob Schluns; Addison Walker; Jake D Jones; Kyle P Quinn; Jamie Hestekin; Jeffrey C Wolchok
Journal:  Biomed Mater       Date:  2017-12-28       Impact factor: 3.715

3.  Rabbit as an animal model for the study of biological grafts in pelvic floor dysfunctions.

Authors:  Marta Peró; Laura Casani; Cristina Castells-Sala; Maria Luisa Pérez; Esther Moga Naranjo; Oriol Juan-Babot; Leticia Alserawan De Lamo; Patricia López-Chicón; Anna Vilarrodona Serrat; Lina Badimon; Oriol Porta Roda
Journal:  Sci Rep       Date:  2021-05-18       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.